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Background: Necrotizing fasciitis is characterized by a fulminant destruction of the soft tissue with an alarmingly high
mortality rate. One of the main reasons for the continued high mortality is due to the challenge to punctual recognize
and diagnose this disease, as specific cutaneous signs can vary or even be missing early in its evolution – especially in
case of simultaneous first manifestation of an acute leukemia.
Case presentation: An untypical case of necrotizing fasciitis disease in a young patient with the first diagnosis of
acute myeloid leukemia is presented. After her induction chemotherapy the only presenting clinical sign was fever
in the presence of severe neutropenia without an evident infectious focus. After a few days a painless confluent,
erythematous, pustular skin rash with a central necrosis on lateral thigh appeared. Escherichia coli was isolated from
blood cultures. Surgical debridement was performed and showed subcutaneous tissue, fascia and underlying muscle
around the site of initial cutaneous manifestation with typical necrosis on exploration. But, initially taken skin biopsy
did not show any typical histopathological findings like bacteria or inflammatory cells confirming necrotizing fasciitis.
Nevertheless, the intraoperative findings were impressive and highly indicative for a necrotizing soft tissue infection,
so that the patient was treated according to clinical guidelines with extensive recurrent surgical debridement,
broad-spectrum antibiotics and intensive care therapy. After recovering from NF, she successfully underwent further
chemotherapy and stem cell transplantation.
Conclusion: The presented case highlights the risk of potential misinterpretation, delayed diagnosis and treatment of
necrotizing fasciitis in patients presenting with an untypical clinical and histopathological manifestation of necrotizing
fasciitis as a result of severe neutropenia following chemotherapy for acute myeloid leukemia.
Keywords: Necrotizing fasciitis, Soft tissue infection, Acute myeloid leukemia, Granulocytopenia, Diagnostic difficultiesBackground
With an incidence of 0.04 per 1000 person-years, necro-
tizing fasciitis (NF) is a rare but fulminant and even life
threatening soft tissue infection [1]. Despite increasing
knowledge about its etiology, predictors, progressive
clinical manifestation and improvements in diagnosis
and therapy, the mortality rate still remains - subject to
its stage and localization - 15 to 46% [2]. NF is character-
ized by a rapid onset of extending inflammation and ne-
crosis involving fascia, muscles and subcutaneous tissues
with a successive affection of the overlying skin. Accord-
ing to microbiological findings it is classified into two
types. Type I NF is a polymicrobial infection, whereas* Correspondence: Mareen.Brumann@med.uni-muenchen.de
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unless otherwise stated.type II NF presents as a monomicrobial bacterial infec-
tion most commonly caused by group A β-hemolytic
streptococci. In most cases, the clinical findings are inad-
equate pain (“pain out of proportion”) regarding the min-
imal changes of the cutis. Therapy consists of immediate
and radical surgical debridement combined with empir-
ical broad-spectrum antibiotic coverage. Although multi-
disciplinary therapy protocols have led to a decrease of
mortality rate in the last decades, there is an increasing
number of immunosuppressed patients (17%) and pa-
tients suffering from hematological malignancies (5%)
who are particularly at risk [3]. Especially, as these pa-
tients do not always present a “typical” etiopathology, NF
remains a critical diagnostic and therapeutic challenge
requiring an early and aggressive surgical intervention for
salvage. We report a case of severe necrotizing fasciitis ofal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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acute myeloid leukemia.
Case presentation
A 30-year-old woman from Saudi-Arabia was admitted
to our department of internal medicine with the strong
suspicion of first manifestation of acute myeloid leukemia.
Laboratory testing showed mild anemia and throm-
bocytopenia with normal leukocyte count. The differen-
tial blood cell count, however, showed 47% leukemic
blasts. A bone marrow biopsy was performed immedi-
ately. With approximately 90% blasts the diagnosis of
acute myeloid leukemia (AML) was confirmed. Flow cy-
tometry showed an expression of CD34, HLA-DR, CD38
and cyMPO. A cross-lineage of CD56 was found, which
correlates with a poor prognosis [4]. Cytogenetics and
molecular analysis of the bone marrow cells revealed
an ETV6-gen deletion in 12p13. According to the
hematologic protocol intensive induction chemotherapy
with HAM (high-dose Ara-C and Mitoxantron) was imme-
diately initiated.
On day 8 after admission (2 days after the first cycle of
chemotherapy was finished) the patient developed neu-
tropenic fever up to a temperature of 39.4°C. The first
laboratory testing showed a decrease in leukocytes down
to 0.4 G/l with a C-reactive protein (CRP) less than
0.1 mg/dl. Escherichia coli with an extended-spectrum
beta-lactamase (ESBL) was isolated from initially taken
blood cultures, whereas all other clinical and diagnostic
examinations (x-ray of the chest, urine, echocardiog-
raphy and ultrasonography) were normal. Empirical
broad-spectrum antibiotics was immediately initiated
with Piperacillin/Tazobactam and switched to Merope-
nem after microbiologic testing confirmed ESBL sepsis.
On that first day of fever, the patient told us, that she fell
in the bathroom hurting her right knee two days before
(day 6 after admission). There was no apparent injury on
her leg. On further clinical examination, besides fever,
her vital signs were always normal. In the course of the
next 2 days neutrophils dropped below 0.1 G/l and CRP
levels soared to a peak of 29.9 mg/dl. Highest procalcito-
nin level (PCT) measured was 1.7 ng/ml. Three days after
the patient suffered from the minor injury to her lateral
thigh, she suddenly presented a small hematoma with
only little pain (day 9 after admission). There were no
signs of superinfection of the hematoma explaining the
clinical and laboratory signs of this unclear systemic in-
fection. On that day, the patient was first presented to
the surgical department. Within the next two days, the
hematoma rapidly changed to a big untypical necrosis of
the skin (day 11 after admission, see Figure 1). Therefore,
the patient was again presented to the surgical depart-
ment. The patient was still in a good general condition
with only little pain. A CT scan was initiated and showedentrapped air under the site of necrosis. Although the
skin manifestation was not typical for a necrotizing soft
tissue lesion, we considered the possibility of an untypical
case of NF during severe neutropenia. Therefore, a surgi-
cal exploration was performed immediately (see Figure 2).
Macroscopically, subcutaneous tissue, fascia and muscle
showed the typical characteristics of necrotizing fasciitis
with grey necrotic tissue, facial edema, vessel thrombosis
and non-contacting muscle. Intraoperative, there was
only minimal resistance dissecting the subcutaneous
fascia off the deep fascia, which is commonly described
as positive “finger test” [5]. The histological findings
showed facial necrosis, vasculitis, thrombosis and sup-
puration of the veins and arteries coursing through the
fascia. But, there were no signs of disease-causing bac-
teria or infiltration of polymorphonuclear leukocytes in
the deep dermis and fascia as expected. First microbio-
logical testing did not find any bacteria. The initial histo-
pathological report could not confirm the typical picture
of necrotizing fasciitis (see Figure 3). In the further
course of time, intensive care medicine was needed. After
confirmation of adequate morphologic blast clearance in
the bone marrow supportive treatment with granulocyte
colony stimulating factor (G-CSF) was added on day 18
(after start of chemotherapy). Neutrophils eventually re-
covered on day 23 (>500/μl). After beginning to recover,
histopathological analyses of additional specimen of sur-
gical resections showed the expected typical pathological
findings like inflammatory cells and bacteria. Further-
more, microbiological testing confirmed ESBL infection.
A multiplicity of operations with extended debridement
was performed in order to eradicate the infection using
negative pressure wound therapy. After successful eradi-
cation the skin defect involved the complete lateral thigh
including nearly the whole circumference of the lower
leg. In the further course of time, the immense skin de-
fects had to be prepared for further reconstructive sur-
gery. Reconstructive surgery with mesh graft harvest was
complicated by the limited residual skin available on the
lower extremity and the delay on wound healing of
the harvest sites. Due to unfavorable cytogenetics and
the complicated course of treatment our patient was
assigned to undergo allogeneic stem cell transplantation
in first remission. But, the transplantation was only pos-
sible with wounds totally closed. It took another six sur-
gical interventions and nearly eight months to finally
close all wounds (see Figure 4). After further recovery the
patient underwent allogeneic stem cell transplantation as
planned. Today, she is doing well and there is no evidence
of disease.
Discussion
Necrotizing fasciitis is a rare, but one of the most se-
vere and potentially highly lethal soft-tissue infection.
Figure 1 Skin manifestation after bagatelle injury on day 11 after admission.
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face long hospitalizations on intensive care units, mul-
tiple reconstructive interventions and intensive rehabili-
tation. Mortality rates have been shown to be determined
by the time and delay of operative intervention [6-9].
Therefore, timing and adequacy of radical, extended op-
erative debridement coupled with supportive broad-
spectrum antibiotics has a substantial influence on the
remaining high mortality [10,11]. To assure patient safety
not only in surgery - a high index of suspicion leading to
the expeditious diagnosis of necrotizing fasciitis followed
by appropriate resuscitation and eradicative surgery is
needed. The diagnosis and distinction of NF from other
less fatal soft tissue infections is still notoriously difficult
and becomes even more challenging if patients’ clinical
presentation is exceptional due to an underlying disease
and its specific therapy.
There are less than 10 cases reported with adults suf-
fering from necrotizing fasciitis secondary to acute mye-
loid leukemia (see [12]). The few instances describing
such cases underline the necessity to consider NF even
if the clinical symptoms, skin manifestation and courseFigure 2 Intraoperative appearance after initial radical debridement oof the patient’s condition might not be typical for NF.
That is particularly applying for cases of malignancy and
following chemotherapy as the subsequent granulocyto-
penia might mask typical findings like fever and high
levels of inflammatory markers in the laboratory diag-
nostic or lead to missing bacteria and inflammatory cells
in the histopathological testing.
We present a young woman with first AML manifest-
ation and subsequent immune suppression due to inten-
sive chemotherapy that went on suffering from a severe
form of necrotizing fasciitis of the lower extremity. Our
case presents a diagnostic challenge given the equivocal
clinical signs – including the skin manifestations and a
potentially misleading histology. This report may help
increase awareness of untypical presentations of necro-
tizing soft-tissue infection in severely immunocomprom-
ised patients.
Although there have been several attempts to identify
special criteria for early diagnosis, necrotizing fasciitis is
a clinical diagnosis depending on verifying operative
findings. As the infection takes its origin in the deep tis-
sue, delayed diagnosis followed by subsequent delayedn day 11 after admission.
Figure 3 Areactive necrosis of subcutaneous fat and fascia
without detection of bacteria (H&E, 200×).
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lows bagatelle injury like stiches, injections, trauma or
more seldom operation or burn injury. Following such a
bagatelle injury, different bacteria are able to induce
necrotizing fasciitis like streptococci, staphylococci, en-
terococci, escherichia coli, and anaerobe bacteria [13].
Characteristically, type II NF is a monomicrobial infec-
tion with streptococci or gram-negative bacteria, which
shows a more rapid and aggressive clinical course than
type I infections. In general, predisposing risk factors
are diabetes mellitus, immune suppression, end-stage
renal failure, pulmonary disease, malignancy (especially
leukemia), and injection drug abuse, which are normally
associated with type I infection, whereas immune com-
petent, healthy people are more often confronted withUntypical necrosis / CT-scan / 1st operation
Progress of infectio
vacuum-therapy, in
Day 0 2 6 8 9 11 12 14 16 22 28 34
Admission to internal medicine department
First diagnosis of AML
Induction chemotherapy with HAM
Bagatelle injury
Neutropenic fever, positive blood cultures (ESBL)
2nd OP
3rd 4th 5th OP
6th OP Debridemen
7th OP S
Figure 4 Diagram of the course of disease.aggressive forms of type II infections [13]. Regarding this
case, our patient suffers from a malignancy (AML) and a
subsequent immune suppression due to chemotherapy,
which normally would have predestinated her to develop a
polymicrobial type I infection. But, in our case, we found a
monomicrobial type II infection as the taken skin rashes
only showed E. coli. Furthermore, E. coli is not a typical
type II category bacterium. Most commonly type II infec-
tions are induced by group A streptococcal bacteria.
The variety and in some cases even absence of early
and specific cutaneous and systemic manifestations may
lead to a potentially fatal failure of immediate recogni-
tion and diagnosis of necrotizing fasciitis. The com-
monly described clinical signs are disproportional pain,
erythema, tenderness, warm and swollen skin, blistering,
skin crepitus and necrosis. But, they are only observed
in 10% to 40% of all patients [8,14,15]. All these afore-
mentioned signs are indicative for a local infection, but
the differentiation between non-necrotizing soft-tissue
infections like cellulitis or erysipelas and necrotizing
soft-tissue infections remains quite difficult. Apparently,
the most constant initial clinical feature (91,1%) is “pain
out of proportion” or so-called “pain extending past
margin of apparent skin infection” compared to physical
finding [13]. In this presented case, our patient showed
only unspecific signs of systemic infection with neutro-
penic fever and a raise of CRP without any infectional
focus two days after last induction chemotherapy (8 days
after admission). She did not present any cutaneous
signs in the first few days. In the course of two more
days she developed a hematoma on the lateral thigh and
asking her she remembered a blunt trauma to her lower
extremity a few days before. She only reported little pain12th OP11th10th9th
n / necrosectomy, debridement,
fect-eradication
Wound conditioning
41 48 59 67 75
t
tart of reconstructive surgery with mesh-grafts
8th OP Second mesh-graft
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ation like hypotension, prostration or even multiple
organ failure have often been described to be helpful in
diagnosing patients suffering from NF [16,17], but have
not been seen in our case. In accordance, Wong and col-
leagues showed in their retrospective study, that only
18% were hypotensive and only 53% presented with high
temperature on admission [8]. Retrospectively, the pre-
sented hematoma was not only due to the bagatelle injury
but the initial sign of a necrotizing fasciitis. Therefore, one
has to keep in mind that patients can appear systemically
quite well despite the presence of necrotizing fasciitis es-
pecially in case of immune suppression - as these patients
are not able to response to infection adequately and skin
manifestation may present different due to their blunted
immunological response system.
In the last decades, a variety of diagnostic tools have
been described to facilitate and hasten the diagnosis of
NF. For instance, Wang et al. established three different
stages of NF according to skin manifestations [18]. They
retrospectively analyzed the cutaneous manifestations of
NF in patients who were not surgically treated for at
least 8 days. Depending on these observations they in-
troduced a staging system correlating with disease’s pro-
gression (early (1), intermediate (2) and late (3) stage).
Following this clinical staging system, patients in stage 1
typically present with tenderness to palpation, erythema
and swollen and warm skin. Patients in stage 2 show blis-
ter and bullae formation as well as skin fluctuance and in-
duration. Patients in stage 3 present with hemorrhagic
bullae, skin anesthesia, crepitus and skin necrosis. Our
patient first did not show any cutaneous manifestation be-
sides a little hematoma after the inadequate trauma to her
upper leg without swelling, erythema or warming. In the
course of time it rapidly changed and her lateral thigh sud-
denly presented with a blistering and a central necrosis
with a surrounding erythema. Following Wang et al. she
did not show the typical first and second stage of NF, but
the late third one without precedent “cutaneous warning
signals”.
Based on laboratory findings, Wong et al. proposed a
numerical scoring system to distinguish necrotizing fasci-
itis from other soft tissue infections, called the LRINEC
(Laboratory Risk Indicator for Necrotizing Fasciitis) score.
This score is calculated by assuming each of the six poten-
tially predictive factors (CRP, WBC, hemoglobin, sodium,
serum creatinine, serum glucose). They are measured upon
admission to classify patients into a group of low-,
intermediate-, and high-risk patients [19]. In our case, we
can retrospectively calculate a LRINEC score of 2, which
correlates - according to presented scoring system -
with a low risk category and a NF probability of less
than 50%. One possible source of error in this scoring
system might be the fact that normally an increase ofleukocytes - as correlating with the systemic infection -
leads to a higher LRINEC score. But this is not the case for
severely immunocompromised patients who cannot de-
velop leukocytosis and therefore underscore in this scoring
system.
Wall et al. established another scoring system using
WBC count and serum sodium levels to diagnose NF.
With a specificity of 76% and a positive predictive value
of 26% it might be of help for the elimination of the
diagnosis of a necrotizing soft tissue infection but not
for the proof of it [20]. Besides the typical inflammatory
markers like CRP, leukocytes and PCT, patients suffering
from NF often present with hypocalcaemia due to the fat
necrosis, acidosis, hypoalbuminemia or hyperuricaemia
[21]. Until now, these mentioned laboratory abnormalities
in patients with NF are only nonspecific findings.
In order to immediately distinguish between necrotiz-
ing and non-necrotizing soft tissue infections a prospective
study was performed to characterized serum cytokine
levels and WBC counts of patients presenting with a high
suspicion of NF in the emergency department. In their
study, Rodriguez et al. found significantly higher levels of
WBC and significantly lower levels of interleukin-1β in pa-
tients with NF compared to those suffering from non-NF
soft tissue infections. There were no significant differences
regarding other potential inflammatory cytokines like
Il-1Ra, IL-6, IL-8 or INF-γ [21]. Although these findings
might be helpful in the early diagnosis of NF, cytokine as-
says needed for an instant screening are not widely avail-
able, which is - at that time - the major limitation.
Trebesius et al. tested fluorescence in situ hybridization
(FISH) and showed that it was a suitable method for the
rapid and cultivation-independent identification of bacter-
ial pathogens. The results of their experimental study de-
scribed an rRNA-targeted oligonucleotide set covering
more than 95% of the pathogens that are associated with
NF. However, they only studied a small sample size and
this method is only an experimental approach so far [22].
Particularly for infectious diseases following a fulmin-
ant live-threatening course, such as NF, a fast and reli-
able detection technique would be of great importance.
But, taking all these investigations into account, a reli-
able and widely available test for the contemporary diag-
nosis of NF is unfortunately still missing.
A further obligatory diagnostic tool, especially in un-
usual cases in which the intraoperative findings are un-
clear, is histology. In untypical cases, the result of the
tissue sample and instantaneous sections might be very
helpful in distinguishing between non-necrotizing soft
tissue infection or necrotizing forms and might thereby
help the surgeon to decide, whether there is a need for
an early second look and repeated debridement. Com-
mon pathologic criteria as described by Stamenkovic
and colleagues to reliably identify NF imply extensive
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dermis-, and fascia-infiltration of polymorphonuclear
leucocytes, fibrinous thrombi of arteries and veins cours-
ing through the fascia, angiitis with fibrinoid necrosis of
arterial and venous walls, presence of microorganisms
within the destroyed fascia and dermis and an absence of
muscle involvement [23]. The histopathological findings
in our presented case were unusual (see Figure 3). The
initial pathological report said that - as there were no
signs of bacteria or inflammatory cells –a necrotizing fas-
ciitis was more or less improbable. In contrast, our intra-
operative findings were typical including the so-called
“dishwater” or “foul-smelling discharge”, necrosis and
loss of the normal resistance of the fascia to finger dissec-
tion, which is called the positive “finger test” [10]. There-
fore, our patient was treated according to NF guidelines
irrespective of the initial histopathological findings. Re-
garding our special case, the initial skin biopsy and
microbiological testing was misleading. In our opinion,
this is most likely due to the fact that our patient suffered
from severe neutropenia and thereby could not respond
to this necrotizing infection adequately. After beginning
recovery, further taken tissue samples then showed the
expected typical inflammatory cells and microbiological
testing confirmed ESBL infection. Considering these
facts - in terms of doubt - the operative exploration
should remain the gold standard modality for the diagno-
sis of NF irrespective of all available diagnostic tools.
The severe granulocytopenia was a key component in
our case. Bone marrow suppression - particularly granu-
locytopenia - is a common feature of AML itself and is
an inevitable side effect of intensive treatment of
leukemia. Our patient showed a severe neutropenia from
right at presentation of disease. Because of persistent
neutropenia with evidence of severe necrotizing soft tis-
sue infection, we decided to start G-CSF therapy on day
18. The decision to start a supportive treatment with
granulocyte colony stimulating factor (G-CSF) in AML
patients is discussed controversially but depends on the
circumstances. One the one hand, G-CSF therapy yields
a certain risk of leukemic blasts induction. One the
other hand, however, administration of this cytokine to
neutropenic leukemia patients has been associated with
a reduction in fever, clinical infections, and length of
hospital stay [24,25]. According to current opinion,
leukocyte response correlates well with a favorable
outcome in children with NF and leukemia notifying
that leukocyte production by bone marrow is essential
for survival of leukemia patients with additional necrotiz-
ing fasciitis [26-28].
In summary, it is essential to accentuate that there are
no mandatory “hard signs” for the diagnosis of necrotiz-
ing fasciitis, which still leads to a missed early diagnosis
in 85% to 100% of all cases [8]. A retrospective analysispointed out, that 35% of later NF has been misinter-
preted like cellulites or severe non-necrotizing soft-
tissue infection [29]. Another retrospective study found
that only 14% of patients with NF were admitted with
the right diagnosis [8].
For this reason - even more in case of malignancy and
immune suppression that might lead to an untypical
clinical presentation - patients depend on a high aware-
ness of the involved physicians and a close cooperation
of all medical faculties to assure patient safety.
Conclusion
The combination of malignancy like AML and subse-
quent severe neutropenia due to chemotherapy increases
the risk of delayed diagnosis and consequent surgical
treatment of necrotizing fasciitis as “typical” skin signs,
systemic manifestations and histopathological findings
might be misleading or even missing according to the
underlying disease. Delayed recognition of NF leading to
consequent massive soft tissue loss and sepsis remains a
potential deadly pitfall in the management of this dis-
ease. To assure patient safety in surgery, a high amount
of suspicion and awareness of the variety of clinical find-
ings is indispensable when confronted with such a com-
plex and fluctuating clinical entity.
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